StudyFinder

Phase 3 Study of MRTX849 +Cetuximab vs Chemo in Patients W/ Advanced Colorectal Cancer w/ KRAS G12C

OPEN TO ACCRUAL
I'm interested

18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
• Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
Exclusion Criteria:

• Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
• Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
• Active brain metastasis

Drug: MRTX849, Biological: Cetuximab, Drug: mFOLFOX6 Regimen, Drug: FOLFIRI Regimen, drug: Mrtx849, drug: Leucovorin, drug: Folinic acid, drug: Cetuximab, drug: 5-fluorouracil

Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Rectum, Colon

Colorectal Cancer, Colorectal Cancer Trial, Colorectal Carcinoma, Rectal Cancer, Colon Cancer, KRAS, KRAS G12C, RAS, Colorectal Adenocarcinoma

Donovan, Carrie - cdonovan2@vcu.edu
Matin, Khalid
III
HM20022574
NCT04793958
See this study on ClinicalTrials.gov

Back